ESC 365 - What have we learned? Long-term safety and efficacy of inclisiran

Open Access

What have we learned? Long-term safety and efficacy of inclisiran

Session: Strategies to reach LDL-C goals in patients with high or very high CV risk: what's new for inclisiran?

Topic: Lipid-Lowering Agents

Speaker: Professor R. Wright (Rochester, US)

Sponsored by Novartis Pharrma

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor R Scott Wright

Mayo Clinic, Rochester (United States of America)

4 presentations

3 followers

3 more presentations in this session

Where are we now? Decision-making in LDL-C lowering and CV risk

Speaker: Professor J. Jukema (Leiden, NL)

Where are we going? Population health and the VICTORION programme

Speaker: Professor K. Ray (London, GB)

Q&A and meeting close

Speaker: Professor J. Jukema (Leiden, NL) Professor R. Wright (Rochester, US) Professor K. Ray (London, GB)

Access the full session

Strategies to reach LDL-C goals in patients with high or very high CV risk: what's new for inclisiran?

Speakers: Professor R. Wright, Professor J. Jukema, Professor K. Ray, Professor J. Jukema, Professor R. Wright...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources